Edwards Lifesciences (EW) Q4 2025: TMTT Grows 40% as Mitral and Tricuspid Pipeline Unlocks Multi-Year Opportunity

2026-02-10 | By EarningsIQ Research

Edwards Lifesciences exited 2025 with accelerating momentum in its transcatheter mitral and tricuspid therapies (TMTT), which surged 40% in Q4, while its core TAVR business sustained high single-digit procedural growth globally. The company’s increased investment in patient access and clinical evidence, coupled with major pipeline launches and evolving treatment guidelines, is positioning Edwards for durable market leadership and multi-layered growth into 2026 and beyond. Investors should monitor the pace of TMTT adoption, the impact of new coverage decisions, and the operational discipline around SG&A as the company navigates a higher bar for growth in the coming year.

Summary

• TMTT Portfolio Expansion: Next-gen launches and rapid adoption are accelerating Edwards’ mitral and tricuspid platform opportunity.
• Guideline-Driven TAVR Momentum: Shifting clinical standards and early treatment evidence are driving urgency and share stability in TAVR.
• Margin Discipline Watchpoint: Elevated SG&A spending for patient access initiatives will test operating leverage in 2026.

Business Overview

Edwards Lifesciences is a global medical technology company focused exclusively on structural heart disease. The business generates revenue through three main segments: TAVR (Transcatheter Aortic Valve Replacement), its flagship percutaneous valve franchise for aortic stenosis; TMTT (Transcatheter Mitral and Tricuspid Therapies), a high-growth platform addressing mitral and tricuspid valve disease; and Surgical Structural Heart products, including bioprosthetic valves and repair solutions for open-heart procedures. The company’s growth is driven by innovation, evidence-based expansion of indications, and increased adoption of less invasive therapies globally.

Performance Analysis

Edwards Lifesciences delivered robust revenue growth in Q4 2025, led by a 40%+ surge in TMTT and double-digit expansion in TAVR. TAVR sales reached $1.16 billion, up 10.6% YoY, with stable global pricing and competitive positioning. The TMTT segment, now surpassing $500 million in annual sales, benefited from continued global adoption of Pascal and Evoque, as well as the initial U.S. launch of Sapien M3. Surgical sales were up modestly, impacted by one-time distributor inventory adjustments, but fundamentals remain intact with Resilia-based therapies gaining share.

Operating margins were pressured in Q4 by a deliberate increase in SG&A spending—notably for patient access initiatives, clinical education, and field resources—yet the company maintained mid-20% adjusted operating margins. Gross margin held steady, reflecting higher manufacturing costs tied to new therapy ramp-ups. FX provided a modest tailwind, and the balance sheet remains strong with $3 billion in cash and significant share repurchase capacity.

• TMTT Growth Acceleration: The segment’s >40% growth and pipeline launches (NextGen Pascal, Sapien M3) are transforming its long-term revenue base.
• TAVR Share Stability: High single-digit procedural growth and “sticky” share gains post-competitor exit support continued category leadership.
• SG&A Investment Spike: Q4 saw a $100M+ YoY increase in SG&A, largely for patient access and education, with a more moderate pace expected in 2026.

Edwards’ financial performance reflects both strong underlying demand and an aggressive investment cycle to expand access and drive future growth. The challenge for 2026 will be to maintain growth momentum while absorbing higher operating costs and navigating tougher year-over-year comparisons.

Executive Commentary

Strategic Positioning

1. TMTT as a Multi-Year Growth Engine

Edwards is leveraging a comprehensive TMTT portfolio—including Pascal, Evoque, and Sapien M3—to address large, underserved patient populations in mitral and tricuspid valve disease. The upcoming launches of NextGen Pascal and U.S. approval for tricuspid indications are poised to extend the segment’s >40% growth trajectory. Management reiterated its $2 billion TMTT revenue target by 2030, underscoring the platform’s centrality to long-term strategy.

2. TAVR’s Durable Leadership, Driven by Evidence and Guidelines

Recent clinical trial data (PARTNER 3, early TAVR) and evolving treatment guidelines in the U.S. and Europe are shifting the treatment paradigm toward earlier intervention and proactive disease management. Edwards’ Sapien platform remains the only TAVR therapy with an asymptomatic indication, and the company is actively shaping referral patterns and clinical practice through education and advocacy partnerships, such as the new Heart Valve Initiative with the AHA.

3. Margin Expansion and Capital Allocation Discipline

While Q4 saw a notable increase in SG&A for strategic initiatives, management reaffirmed its commitment to operating margin expansion—targeting 150 basis points of improvement in 2026 and 50–100 basis points annually thereafter. The company continues to prioritize business investment, pipeline M&A, and opportunistic share repurchases, with $2 billion in remaining buyback authorization.

4. Surgical Innovation and Adjacent Expansion

Edwards is extending its surgical heart franchise with Resilia tissue durability data, new mitral valve solutions, and a measured entry into the left atrial appendage closure (LAAC) market—a complementary, high-unmet-need segment. The LAAC rollout will be gradual, but management sees it as a future growth lever for the surgical business.

5. Regulatory and Coverage Catalysts

Potential updates to the U.S. National Coverage Determination (NCD) for TAVR and evolving Japanese guidelines represent meaningful tailwinds for access and market expansion starting in late 2026 and beyond. Management cautions that NCD changes will have negligible impact in 2026 but could drive incremental growth in subsequent years.

Key Considerations

The 2025 finish sets a high bar for 2026, with Edwards balancing aggressive investment in access and innovation against the need for sustained margin expansion. The strategic context is defined by:

Key Considerations:

• TMTT Pipeline Execution: The pace of new product launches and global adoption will determine whether TMTT can sustain its outsized growth and reach the $2B 2030 target.
• Guideline and Policy Shifts: Recent changes in European and pending U.S. TAVR guidelines are shifting treatment patterns, but require significant education and field investment to realize full market impact.
• SG&A Leverage: Elevated Q4 spending on patient access and field resources must translate to durable share gains and volume growth to justify margin compression.
• Moderate AS Opportunity: The pending PROGRESS trial results for moderate aortic stenosis could unlock a large new patient population, but management is taking a cautious, evidence-first approach.

Risks

Key risks for Edwards include the potential for slower-than-expected TMTT adoption, margin pressure if SG&A investments do not yield sufficient volume gains, and uncertainty around regulatory and reimbursement outcomes (notably the timing and scope of TAVR NCD updates). Competitive dynamics, particularly in Europe post-competitor exit, could also affect share stability. Management’s heavy reliance on clinical evidence and guideline shifts brings execution risk if trial results or adoption pace fall short of expectations.

Forward Outlook

For Q1 2026, Edwards guided to:

• Sales of $1.55 to $1.63 billion, with reported growth aided by FX tailwinds
• Adjusted EPS of $0.70 to $0.76, reflecting mid-teens growth at the midpoint

For full-year 2026, management reaffirmed guidance:

• Sales growth of 8–10% (constant currency)
• EPS of $2.90 to $3.05

Management highlighted several factors that shape the 2026 outlook:

• Stronger growth in the first half, with tougher comps and normalized seasonality in the back half
• Minimal impact from TAVR NCD changes in 2026, with more relevance in 2027 and beyond

Takeaways

Edwards Lifesciences enters 2026 with strong momentum, but faces a higher bar for growth and profitability as it scales next-gen therapies and absorbs elevated SG&A.

• TMTT Inflection: Rapid adoption and new launches are transforming the company’s growth profile, but execution on training, access, and outcomes will be critical to sustain momentum.
• TAVR Resilience: Evidence-driven shifts in clinical practice and proactive disease management are reinforcing Edwards’ leadership, but competitive and regulatory dynamics remain in flux.
• Margin Management: Investors should closely watch whether Q4’s step-up in strategic spending translates into durable share gains and operating leverage in 2026 and beyond.

Conclusion

Edwards Lifesciences delivered a strong Q4, with TMTT emerging as a multi-year growth engine and TAVR benefiting from evidence-based urgency and stable share. The company’s aggressive investment in access and innovation raises the stakes for operational discipline as it pursues double-digit growth and expanding margins in 2026 and beyond.

Industry Read-Through

Edwards’ results and commentary signal an accelerating shift in the structural heart market toward earlier intervention, guideline-driven care, and multi-modality portfolios. The rapid adoption of transcatheter mitral and tricuspid therapies highlights the importance of comprehensive, evidence-backed platforms and physician education. Competitors in the valve space will need to match Edwards’ pace of innovation, clinical data generation, and market shaping initiatives to defend or gain share. The evolving reimbursement landscape, particularly in the U.S., will be a key determinant of market expansion and access for all players in the coming years.

EW Healthcare Medical Devices Structural Heart TAVR TMTT Margin Expansion Pipeline